Compare Align Technology, Inc. (ALGN) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Align Technology, Inc. vs TransMedics Group Inc — how do they compare? Align Technology, Inc. trades at $173.38 (market cap $12.29B), while TransMedics Group Inc trades at $87.08 (market cap $3.10B). The key difference: Align Technology, Inc. is far larger — about 4× TransMedics Group Inc's market cap, and Align Technology, Inc. is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| ALGN | TMDX | |
|---|---|---|
Market Cap | $12.29B | $3.10B |
Sector | Health | Technology |
52-Week High | $197.51 | $150.42 |
52-Week Low | $124.88 | $61.99 |
Enterprise Value | $11.30B | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALGN trades at $174.63, down 0.8% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating estimates with record revenue and clear aligner volume. Fundamentals show solid profitability with a 68.05% gross margin and 9.99% net income margin, though revenue growth has moderated. Recent news highlights a patent win in China and strategic initiatives following activist investor engagement.
The outlook is mixed: analyst consensus is strongly bullish (73% buy ratings), but technicals and slowing revenue growth pose near-term risks. Investment opportunity lies in international expansion and digital dentistry platform growth, while risks include competitive pressures and execution of new strategic initiatives. The stock's valuation at 30x P/E requires sustained earnings growth to justify.
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Align Technology, Inc.
Align is the leading manufacturer of clear dental aligners globally, having pioneered the technology with the introduction of its Invisalign branded aligners in 1998. Since then, Invisalign has become a household name, having treated over 10 million patients with malocclusion (misaligned teeth) through orthodontist and dentist-guided treatment plans. The company maintains dominant market share of clear aligners, despite the introduction of direct-to-consumer competitors upon the expiration of key patents that began in 2017. Align also manufactures intraoral scanners (iTero), used for orthodontic treatment and restorative dental procedures (digital models for crowns, veneers, and implants).
Read more on ALGN →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
